Orthocell Ltd (AU:OCC)
ASX:OCC
Want to see AU:OCC full AI Analyst Report?
OCC Stock Chart & Stats
AU$0.81
AU$0.07(4.58%)
At close: 4:00 PM EST
AU$0.81
AU$0.07(4.58%)
Day’s Range― - ―
52-Week RangeAU$0.70 - AU$1.70
Previous CloseN/A
Volume2.26M
Average Volume (3M)820.75K
Market Cap
AU$256.39M
Enterprise ValueAU$187.79M
Total Cash (Recent Filing)AU$44.37M
Total Debt (Recent Filing)AU$835.79K
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding271,307,950
10 Day Avg. Volume747,972
30 Day Avg. Volume820,745
Financial Highlights & Ratios
PEG Ratio-3.76
Price to Book (P/B)18.08
Price to Sales (P/S)34.89
P/FCF Ratio-29.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.21Price Target Upside48.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$12.23M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA very low debt-to-equity ratio (0.04) provides durable financial flexibility, reducing insolvency risk and preserving capacity to fund R&D, regulatory work, or manufacturing scale-ups without heavy interest burdens. This structural conservatism supports multi-month strategic initiatives.
Sustained Revenue GrowthConsistent top-line expansion (~19.6% latest year) indicates growing commercial traction for products and services. Durable revenue growth underpins future margin improvement potential and provides a base for scaling manufacturing, distribution and clinical adoption over the next several months.
Specialised Regenerative-medicine FocusA focused portfolio in orthopaedics and autologous cell therapies targets high-barrier clinical markets. Technical and regulatory complexity creates defensible niches and long sales cycles, which favor companies with specialized manufacturing and clinical relationships for sustained market position.
Bears Say
Persistently Negative ProfitabilityOngoing negative net and EBIT margins reflect structural inability to convert revenue into profit. Over months this limits reinvestment capacity, prolongs reliance on external funding, and constrains ability to execute commercialization and R&D programs without dilutive financing.
Negative Operating Cash FlowNegative operating cash flow is a durable operational weakness: it forces dependence on financing or equity raises to fund day-to-day operations and scaling. Even with improved free cash flow growth, persistent OCF deficits raise execution and liquidity risk over the medium term.
Small Operating ScaleA workforce of 37 suggests limited internal capacity for simultaneous manufacturing scale-up, regulatory submissions, and commercial rollout. Scaling in regulated biologics requires hires and systems that raise fixed costs and execution risk, making growth delivery more uncertain.
Orthocell Ltd News
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.70 and its highest was AU$1.70 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$256.39M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 127 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.021.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate is 0.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 271,307,950 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthocell Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.21 (48.77% Upside)
AU$1.21 (48.77% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 97%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$56.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.48%
12-Months-Change
Fundamentals
Return on Equity
-44.80%
Trailing 12-Months
Asset Growth
49.36%
Trailing 12-Months
Company Description
Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
OCC Stock 12 Month Forecast
Average Price Target
AU$1.21
▲(48.77% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---